文献速递乳腺癌

曲妥珠单抗美坦新联合卡培他滨对比单药治疗经治HER2阳性转移性乳腺癌的1期及随机2期试验

Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial.
PubMed 文献 · JAMA Oncol · 2020-01-01

该研究包含1期剂量探索和2期随机对照两部分。1期确定卡培他滨联合T-DM1的最大耐受剂量为700 mg/m2(每日两次)。

要点

  • 1期确定卡培他滨联合T-DM1的最大耐受剂量为700 mg/m2(每日两次,第1-14天,3周周期)。
  • 联合组3-4级不良事件发生率为44%,单药组为41%,未报告5级不良事件。

核心结论

  • 在经治HER2阳性转移性乳腺癌患者中,T-DM1联合卡培他滨相比T-DM1单药并未显著提高客观缓解率。
  • 联合组不良事件更多,但未观察到预期外毒性。

研究设计与样本

  • 1期采用3+3设计评估卡培他滨联合T-DM1的最大耐受剂量,卡培他滨设750、700、650 mg/m2三个剂量水平。
  • 2期为开放标签、随机、国际多中心研究,将转移性乳腺癌患者按1:1随机分配至联合组(n=81)或T-DM1单药组(n=80)。
  • 1期转移性乳腺癌队列接受卡培他滨(每日两次,第1-14天,3周周期)联合T-DM1 3.6 mg/kg每3周;局部晚期/转移性胃癌队列接受卡培他滨(转移性乳腺癌1期最大耐受剂量,必要时降阶梯)联合T-DM1 2.4 mg/kg每周。
  • 2期主要终点为研究者评估的客观缓解率。

主要发现

  • 1期确定卡培他滨联合T-DM1的最大耐受剂量为700 mg/m2(每日两次),基于11例转移性乳腺癌和6例局部晚期/转移性胃癌患者的剂量限制性毒性评估。
  • 联合组82例中78例(95%)报告不良事件,其中36例(44%)发生3-4级不良事件;单药组78例中69例(88%)报告不良事件,其中32例(41%)发生3-4级不良事件;未报告5级不良事件。

关键数值与推荐

  • 卡培他滨联合T-DM1的1期最大耐受剂量为700 mg/m2(每日两次,第1-14天,3周周期)。

临床怎么用

  • 对于经治HER2阳性转移性乳腺癌,在T-DM1基础上加用卡培他滨未显示客观缓解率获益,且不良事件增加,不支持该联合方案作为常规选择。
  • 卡培他滨联合T-DM1的最大耐受剂量为700 mg/m2(每日两次),可作为未来联合方案设计的参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: ERBB2 (HER2)-targeted therapy provides benefits in metastatic breast cancer (mBC) and gastric cancer, but additional treatments are needed to maximize efficacy and quality of life. OBJECTIVE: To determine maximum tolerated doses (MTDs) of trastuzumab emtansine (T-DM1) plus capecitabine in patients with previously treated ERBB2-positive mBC and locally advanced/metastatic gastric cancer (LA/mGC) (phase 1) and the efficacy and safety of this combination vs T-DM1 alone in patients with mBC (phase 2). DESIGN, SETTING, AND PARTICIPANTS: The MTD in phase 1 was assessed using a 3 + 3 design with capecitabine dose modification. Phase 2 was an open-label, randomized, international multicenter study of patients with mBC treated with T-DM1 plus capecitabine or T-DM1 alone. Eligible patients had previously treated ERBB2-positive mBC or LA/mGC with no prior chemotherapy treatment for advanced disease. INTERVENTIONS: Patients in the phase 1 mBC cohort received capecitabine (750 mg/m2, 700 mg/m2, or 650 mg/m2 twice daily, days 1-14 of a 3-week cycle) plus T-DM1 3.6 mg/kg every 3 weeks. Patients with LA/mGC received capecitabine at the mBC phase 1 MTD, de-escalating as needed, plus T-DM1 2.4 mg/kg weekly. In phase 2, patients with mBC were randomized (1:1) to receive capecitabine (at the phase 1 MTD) plus T-DM1 or T-DM1 alone. MAIN OUTCOMES AND MEASURES: The phase 1 primary objective was to identify the MTD of capecitabine plus T-DM1. The phase 2 primary outcome was investigator-assessed overall response rate (ORR). RESULTS: In phase 1, the median (range) age was 54.0 (37-71) and 57.5 (53-70) years for patients with mBC and patients with LA/mGC, respectively. The capecitabine MTD was identified as 700 mg/m2 in 11 patients with mBC and 6 patients with LA/mGC evaluable for dose-limiting toxic effects. In phase 2, between October 2014 and April 2016, patients with mBC (median [range] age, 52.0 [28-80] years) were randomized to receive combination therapy (n = 81) or T-DM1 (n = 80). The ORR was 44% (36 of 81 patients) and 36% (29 of 80 patients) in the combination and T-DM1 groups, respectively (difference, 8.2%; 90% CI, -4.5 to 20.9; P = .34; clinical cutoff, May 31, 2017). Adverse events (AEs) were reported in 78 of 82 patients (95%) in the combination group, with 36 (44%) experiencing grade 3-4 AEs, and 69 of 78 patients (88%) in the T-DM1 group, with 32 (41%) experiencing grade 3-4 AEs. No grade 5 AEs were reported. CONCLUSIONS AND RELEVANCE: Adding capecitabine to T-DM1 did not statistically increase ORR associated with T-DM1 in patients with previously treated ERBB2-positive mBC. The combination group reported more AEs, but with no unexpected toxic effects. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01702558.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Cortés J, Diéras V, Lorenzen S, et al. Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial. JAMA Oncol. 2020. PMID: 32584367. doi:10.1001/jamaoncol.2020.1796

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。